Short answer
Candel Therapeutics, Inc. (CADL) filed an 8-K current report with the SEC on June 24, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). Stockholders elected all four Class II directors, extending their terms through the 2029 annual meeting.
Candel Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Stockholders elected all four Class II directors, extending their terms through the 2029 annual meeting
- Paul B. Manning received the strongest support, with 31,591,618 votes for and 102,352 withheld
- Edward J. Benz received comparatively lower support, with 24,897,348 votes for and 6,796,622 withheld
- KPMG LLP ratified as independent auditor for fiscal 2026, with 53,543,020 votes for
- Director elections included 22,175,525 broker non-votes, limiting interpretation of shareholder participation beyond votes cast
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Candel Therapeutics, Inc. 8-K filings
Get the next CADL 8-K as it lands
Follow CADL for push alerts, or ask the research agent what this filing means.